Genetics of rare diseases of the kidney: Learning from mouse models

Cytogenetic and Genome Research

Volumn 105, Issue 2-4, 2004, Pages 479-484

  Zoja, C ^a   Morigi, M ^a   Benigni, A ^a   Remuzzia, G ^a,b  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIOXIDANT; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IMMUNOGLOBULIN G1; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN TYROSINE KINASE INHIBITOR; RAMIPRIL; RECOMBINANT GAMMA INTERFERON; STEROID; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; VASOPRESSIN ANTAGONIST;

ALPORT SYNDROME; AUTOSOMAL DISORDER; DIALYSIS; FABRY DISEASE; GENE THERAPY; GENETIC DISORDER; GENETICS; HUMAN; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; KIDNEY DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; NEPHRITIS, HEREDITARY; POLYCYSTIC KIDNEY DISEASES; RARE DISEASES;

EID: 3242814501     PISSN: 14248581     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078222     Document Type: Review

References (71)

1. Abbate M, Remuzzi G: Renoprotection: Clues from knockout models of rare diseases. Kidney Int 63:764-766 (2003).
2. Andrews KL, Mudd JL, Li C, Miner JH: Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome. Am J Pathol 160:721-730 (2002).
3. Barker DE, Hostikka SL, Zhou J, Show LT, Oliphant AR, Gerken SC, Gregory MC, Skolnick MH, Atkin CL, Tryggvason K: Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 248:1224-1227 (1990).
4. Berden JHM, Licht R, van Bruggen MCJ, Tax WJM: Role of nucleosomes for induction and glomerular binding of autoantibodies in lupus nephritis. Curr Opin Nephrol Hypertens 8:299-306 (1999).
5. Bishop DF, Calhoun DH, Bernstein HS, Hantzopoulos P, Quinn M, Desnick RJ: Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc Natl Acad Sci USA 83:4859-4863 (1986).
6. Bishop DF, Kornreich R, Desnick RJ: Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3′ untranslated region. Proc Natl Acad Sci USA 85:3903-3907 (1988).
7. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L: Enzymatic defect in Fabry's disease: Ceramidetrihexosidase deficiency. New Engl J Med 276:1163-1167 (1967).
8. Breunig F, Weidemann F, Beer M, Eggert A, Krane V, Spindler M, Sandstede J, Strotmann J, Wanner C: Fabry disease: Diagnosis and treatment. Kidney Int 63:S181-S185 (2003a).
9. Breunig F, Knoll A, Wanner C: Enzyme replacement therapy in Fabry disease: clinical implications. Curr Opin Nephrol Hypertens 12:491-495 (2003b).
10. Callis I, Vila A, Carrera M: Long-term effects of cyclosporine A in Alport's syndrome. Kidney Int 55:1051-1056 (1999).
11. Corna D, Morigi M, Facchinetti D, Bertani T, Zoja C, Remuzzi G: Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 51:1583-1589 (1997).
12. Cosgrove D, Meehan DT, Grunkemeyer JA, Kornak JM, Sayers R, Hunter WJ, Samuelson GC: Collagen COL4A3 knockout: A mouse model for autosomal Alport syndrome. Genes Dev 10:2981-2992 (1996).
13. Cosgrove D, Rodgers K, Meehan D, Miller C, Bovard K, Gilroy A, Gardner H, Kotelianski V, Gotwals P, Amatucci A, Kalluri R: Integrin α1β1 and transforming growth factor-β1 play distinct roles in Alport glomerular pathogenesis and serve as dual targets for metabolic therapy. Am J Pathol 157:1649-1659 (2000).
14. Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dikman S, Fallon JT, Brodie S, Stacy CB, Mehta D, Parsons R, Norton K, O'Callaghan M, Desnick RJ: A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68:711-722 (2001).
15. Foster MH: Relevance of systemic lupus erythematosus nephritis animal models to human disease. Semin Nephrol 19:12-24 (1999).
16. Foster MH, Kelley VR: Lupus nephritis: Update on pathogenesis and disease mechanisms. Semin Nephrol 19:173-181 (1999).
17. Gross O, Beirowski B, Keopke M-L, Kuck J, Reiner M, Addicks K, Smyth N, Schulze-Lohoff E, Weber M: Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 63:438-446 (2003).
18. Guay-Woodford L, Muecher G, Hopkins S, Avner E, Germino G, Guillot A, Herrin J, Holleman R, Irons D, Primack W, Thomson P, Waldo F, Lunt P, Zerres K: The severe perinatal form of autosomal recessive polycystic kidney disease (ARPKD) maps to chromosome 6p21.1→p12: Implications for genetic counseling. Am J Hum Genet 56:1101-1107 (1995).
19. Guay-Woodford LM, Wright CJ, Walz G, Churchill GA: Quantitative trait loci modulate renal cystic disease severity in the mouse bpk model. J Am Soc Nephrol 11:1253-1260 (2000).
20. Heidet L, Borza DB, Jouin M, Sich M, Mattei MG, Sado Y, Hudson BG, Hastie N, Antignac C, Gubler M-C: A human-mouse chimera of the alpha3alpha4alpha5( IV) collagen promoter rescues the renal phenotype in Col4a3-/- Alport mice. Am J Pathol 163:1633-1644 (2003).
21. Heikkila P, Tryggvason K, Thorner P: Animal models of Alport syndrome: advancing the prospects for effective human gene therapy. Exp Nephrol 8:1.7 (2000).
22. Heikkila P, Tibell A, Morita T, Chen Y, Wu G, Sado Y, Ninomiya Y, Pettersson E, Tryggvason K: Adenovirus-mediated transfer of type IV collagen alpha 5 chain cDNA into swine kidney in vivo: deposition of the protein into the glomerular basement membrane. Gene Therapy 8:882-890 (2001).
23. Howie JB, Helyer BJ: The immunology and pathology of NZB mice. Adv Immunol 9:215-266 (1968).
24. Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG: Alport's syndrome, Goodpasture's syndrome, and type IV collagen. New Engl J Med 348:2543-2556 (2003).
25. Iakoubova O, Dunshkin H, Beier D: Localization of a murine recessive polycystic kidney disease mutation and modifying loci that affect disease severity. Genomics 26:107-114 (1995).
26. Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ: Fabry disease: Preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet 68:14-25 (2001).
27. Jung S-C, Han IH, Limaye A, Xu R, Gelderman MP, Zerfas P, Tirumalai K, Murray GJ, During MJ, Brady RO, Qasba P: Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Natl Acad Sci USA 98:2676-2681 (2001).
28. Kim K, Drummond I, Ibraghimov-Beskrovnaya O, Klinger K, Arnaout MA: Polycystin 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci USA 97:1731-1736 (2000).
29. Lawson BR, Prud'homme GJ, Chang Y, Gardner HA, Kuan J, Kono DH, Theofilopoulos AN: Treatment of murine lupus with cDNA encoding IFN-gamma R/Fc. J Clin Invest 106:207-215 (2000).
30. Lemmink HH, Mochizuki T, van de Heuvel LPWJ, Schroder CH, Barrientos A, Monnens LAH, van Oost BA, Brunner HG, Reeders ST, Smeets HJM: Mutations in the type IV collagen α3 (COL4A3) gene in autosomal recessive Alport syndrome. Hum Mol Genet 3:1269-1273 (1994).
31. Lu W, Peissel B, Babakhanlou H, Pavlova A, Geng L, Fan X, Larson C, Brent G, Zhou J: Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation. Nat Genet 17:179-181 (1997).
32. Lu W, Fan X, Basora N, Babakhanlou H, Law T, Rifai N, Harris PC, Perez-Atayde AR, Rennke HG, Zhou J: Late onset of renal and hepatic cysts in Pkd1-targeted heterozygotes. Nat Genet 21:160-161 (1999a).
33. Lu W, Phillips CL, Killen PD, Hlaing T, Harrison WR, Elder FF, Miner JH, Overbeek PA, Meisler MH: Insertional mutation of the collagen genes Col4a3 and Col4a4 in a mouse model of Alport syndrome. Genomics 61:113-124 (1999b).
34. Mageed RA, Prud'homme GJ: Immunopathology and the gene therapy of lupus. Gene Therapy 10:861-874 (2003).
35. Miner JH, Sanes JR: Molecular and functional defects in kidneys of mice lacking alphacollagen3(IV): Implications for Alport syndrome. J Cell Biol 135:1403-1413 (1996).
36. Mochizuki T, Lemmink HH, Mariyama M, Antignac C, Gubler MC, Pirson Y, Verellen-Dumoulin C, Chan B, Schroder CH, Smeets HJ, Reeders ST: Identification of mutations in the α3(IV) and α4(IV) collagen genes in autosomal recessive Alport syndrome. Nat Genet 8:77-82 (1994).
37. Mohan C: Murine lupus genetics: Lessons learned. Curr Opin Rheumatol 13:352-360 (2001).
38. Morel L, Wakeland ED: Susceptibility to lupus nephritis in the NZB/W model system. Curr Opin Immunol 10:718-725 (1998).
39. Nguyen C, Limaye N, Wakeland EK: Susceptibility genes in the pathogenesis of murine lupus. Arthritis Res 4:S255-S263 (2002).
40. Ohshima T, Murray GJ, Nagle JW, Quirk JM, Kraus MH, Barton NW, Brady RO, Kulkarni AB: Structural organization and expression of the mouse gene encoding alpha-galactosidase A. Gene 166:277-280 (1995).
41. Ohshima T, Murray GJ, Swaim WD, Longenecker G, Quirk JM, Cardarelli CO, Sugimoto Y, Pastan I, Gottesman MM, Brady RO, Kulkarni AB: α-Galactosidase A deficient mice: A model of Fabry disease. Proc Natl Acad Sci USA 94:2540-2544 (1997).
42. Ohshima T, Schiffmann R, Murray GJ, Kopp J, Quirk JM, Stahl S, Chan C-C, Zerfas P, Tao-Cheng J-H, Ward JM, Brady RO, Kulkarni AB: Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc Natl Acad Sci USA 96:6423-6427 (1999).
43. Orellana SA, Sweeney WE, Neff CD, Avner ED: Epidermal growth factor receptor expression is abnormal in murine polycystic kidney. Kidney Int 47:490-499 (1995).
44. Park J, Murray GJ, Limaye A, Quirk JM, Gelderman MP, Brady RO, Qasba P: Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer. Proc Natl Acad Sci USA 100:3450-3454 (2003).
45. Pei Y, Watnick T, He N, Wang K, Liang Y, Parfrey, P, Germino G, St George-Hyslop P: Somatic PKD2 mutations in individual kidney and liver cysts support a "two-hit" model of cystogenesis in type 2 autosomal dominant polycystic kidney disease. J Am Soc Nephrol 10:1524-1529 (1999).
46. Peters DJM, Breuning MH: Autosomal dominant polycystic kidney disease: modification of disease progression. Lancet 358:1439-1444 (2001).
47. Proesmans W, Knockaert H, Trouet D: Enalapril in paediatric patients with Alport syndrome: two years' experience. Eur J Pediatr 159:430-433 (2000).
48. Qian F, Watnick TJ, Onuchic LF, Germino GG: The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell 87:979-987 (1996).
49. Qian Q, Harris PC, Torres VE: Treatment prospects for autosomal-dominant polycystic kidney disease. Kidney Int 59:2005-2022 (2001).
50. Qin G, Takenaka T, Telsch K, Kelley L, Howard T, Levade T, Deans R, Howard BH, Malech HL, Brady RO, Medin JA: Preselective gene therapy for Fabry disease. Proc Natl Acad Sci USA 98:3428-3433 (2001).
51. Raz E, Dudler J, Lotz M, Baird SM, Berry CC, Eisenberg RA, Carson DA: Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery. Lupus 4:286-292 (1995).
52. Reeders ST: Multilocus polycystic disease. Nat Genet 1:235-237 (1992).
53. Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, Myers M, Quirk JM, Zirzow GC, Borowski M, Loveday K, Anderson T, Gillespie F, Oliver KL, Jeffries NO, Doo E, Liang TJ, Kreps C, Gunter K, Frei K, Crutchfield K, Selden RF, Brady RO: Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 97:364-370 (2000).
54. Schiffmann R, Koop JB, Austin HA, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO: Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 285:2743-2776 (2001).
55. Sessa A, Meroni M, Battini G, Righetti M, Maglio A, Tosoni A, Nebuloni M, Vago G, Giordano F: Renal involvement in Anderson-Fabry disease. J Nephrol 16:310-313 (2003).
56. Sutters M, Germino GG: Autosomal dominant polycystic kidney disease: Molecular genetics and pathophysiology. J Lab Clin Med 141:91-101 (2003).
57. Sweeney WE, Chen Y, Nakanishi K, Frost P, Avner ED: Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int 57:33-40 (2000).
58. Sweeney WE, Hamahira K, Sweeney J, Garcia-Gatrell M, Frost P, Avner ED: Combination treatment of PKD utilizing dual inhibition of EGF-receptor activity and ligand bioavailability. Kidney Int 64:1310-1319 (2003).
59. Takahashi H, Hirai Y, Migita M, Seino Y, Fukuda Y, Sakuraba H, Kase R, Kobayashi T, Hashimoto Y, Shimada T: Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Proc Natl Acad Sci USA 99:13777-13782 (2002).
60. Takiguchi M, Murakami M, Nakagawa I, Saito I, Hashimoto A, Uede T: CTLA4 IgG gene delivery prevents autoantibody production and lupus nephritis in MRL/lpr mice. Life Sci 66:991-1001 (2000).
61. Theophiloulos AN, Dixon FJ: Murine models of lupus systemic erythematosus. Adv Immunol 37:269-290 (1985).
62. Tomasoni S, Noris M, Zappella S, Gotti E, Casiraghi F, Bonazzola S, Benigni A, Remuzzi G: Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. J Am Soc Nephrol 9:1202-1212 (1998).
63. Upadhya P, Churchill G, Birkenmeier E, Barker J, Frankel W: Genetic modifiers of polycystic kidney disease in intersubspecific KAT2J mutants. Genomics 58:129-137 (1999).
64. van Bruggen MC, Walgreen B, Rijke TPM, Berden JHM: Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 9:1407-1415 (1998).
65. Wakeland EK, Liu K, Graham RR, Behrens TW: Delineating the genetic basis of systemic lupus erythematosus. Immunity 15:397-408 (2001).
66. Woo D, Miao S, Tran T: Progression of polycystic kidney disease in cpk mice is a quantitative trait under polygenic control (Abstract). J Am Soc Nephrol 6:731A (1995).
67. Woo D, Nguyen D, Khatibi N, Olsen P: Genetic identification of two major modifier loci of polycystic kidney disease progression in pcy mice. J Clin Invest 100:1934-1940 (1997).
68. Wu G, D'Agati V, Cai Y, Markowitz G, Hoon Park J, Reynolds MD, Maeda Y, Le TC, Hou H, Kucherlapati R, Edelmann W, Somlo S: Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell 93:177-188 (1998).
69. Zoja C, Liu X-H, Donadelli R, Abbate M, Testa D, Corna D, Taraboletti G, Vecchi A, Dong QG, Rollins BJ, Bertani T, Remuzzi G: Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice. J Am Soc Nephrol 8:720-729 (1997).
70. Zoja C, Corna D, Benedetti G, Morigi M, Donadelli R, Guglielmotti A, Pinza M, Bertani T, Remuzzi G: Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int 53:726-734 (1998).
71. Zoja C, Benigni A, Noris M, Corna D, Casiraghi F, Pagnoncelli M, Rottoli D, Abbate M, Remuzzi G: Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney Int 60:653-663 (2001).